-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
preface
prefaceIn 2022, M&A transaction activity in the global healthcare sector continued to be active
.
From the perspective of mergers and acquisitions, leading enterprises focus on increasing their layout in the fields of kidney disease drugs, neurological disease drugs, inflammatory drugs, rare disease drugs, vaccines and health management services, so as to further strengthen their R&D pipelines, investment in R&D and upcoming blockbuster products
.
From the investment stage, the focus of investment gradually shifts to high-quality late-stage assets and new technologies
that can achieve medical breakthroughs at an early stage.
In terms of M&A scale, the total number of global TOP10 M&A events reached 61.
6 billion US dollars, of which CSL, a leading Australian blood product and vaccine company, acquired Vifor for 117 US dollars
Pharma became the largest M&A event of the year, with Pfizer, United Health and GlaxoSmithKline accounting for 70% of
the top 10 M&A events.
Table 1: Top 10 M&A transactions in the global healthcare sector in 2022
Source: Flint Creation, compiled according to publicly available information
01 CSL11.
7 billion acquires Vifor Pharma
7 billion
In August 2022, Australian blood products and vaccines giant CSL completed the acquisition
of Switzerland's Vifor Pharma for US$11.
7 billion.
Vifor
Headquartered in Switzerland, Pharma is a pharmaceutical company focused on kidney disease and aims to be a global leader in iron deficiency, kidney disease and cardio-kidney therapies, with a focus on chronic diseases
.
Vifor's expertise in the development of new drugs in the fields of iron deficiency, kidney disease and rare diseases is highly compatible with CSL's R&D pipeline and can enrich CSL's development pipeline
.
Through this acquisition, CSL will be able to obtain Vifor's technology patents for the treatment of iron deficiency, kidney and heart and kidney diseases, increase its treatment methods for kidney disease and iron deficiency, diversify its products, and have its production sites
in Switzerland and Portugal.
02 Pfizer acquires Biohaven for $11.
6 billion
6 billion
In October 2022, Pfizer completed its acquisition
of Biohaven for $11.
6 billion.
Biohaven is a neurological disease drug development company, Biohaven combines in-house assets with intellectual property licensed by leading biopharmaceutical companies and academic institutions, and rapidly develops multiple compounds
such as calcitonin gene-associated peptide (CGRP) receptor antagonism, glutamate regulation, and bone marrow peroxidase (MPO) inhibition in clinical trials.
The company's Nurtec product is the world's first and only CGRP receptor antagonist with a rapidly dissolving oral disintegration tablet form and the only drug
that can be used simultaneously to treat and prevent migraine.
With this acquisition, Pfizer has access to a promising range of calcitonin gene-associated peptide (CGRP) receptor antagonists, including NURTEC®
ODT (rimegepant), Zavegepant, and a portfolio of preclinical CGRP assets
.
03 United Health acquires Change Healthcare for $7.
8 billion
8 billion
In September 2022, United Health Group, the largest health insurance company in the United States, acquired Change, a medical informatics company, for US$7.
8 billion
The Healthcare transaction was approved
by the U.
S.
District Court for the District of Columbia.
The deal was previously the subject of antitrust litigation by the U.
S
.
Department of Justice because it believed that the deal would give United Health control over vast amounts of health care data, hurting competition in the commercial health insurance market and a technology market used by health insurers to process health insurance claims and reduce healthcare costs.
Change
Healthcare is a leading healthcare technology platform that provides data and analytics-driven solutions to improve clinical, financial, and patient engagement outcomes
in the U.
S.
healthcare system.
With this acquisition, United Health Group will change
Healthcare merged with the Optum segment to support the fast-growing Optum business segment in processing drug claims, providing care and technical support, among other business segments
.
04 Pfizer acquires Arena Pharmaceuticals for $6.
7 billion
7 billion
In March 2022, Pfizer completed an all-cash acquisition of Arena for $100 per share
All of Pharmaceuticals' outstanding shares are traded in a total of approximately $6.
7 billion.
Arena is a clinical-stage innovative therapeutics R&D company in the area of immuno-inflammatory diseases, with a portfolio of several development-stage therapeutic candidates in gastroenterology, dermatology and cardiology
.
Among them, the focus is on the development of Etrasimod
A new generation of oral S1P modulators for the treatment of a range of immunoinflammatory diseases, including gastrointestinal and dermatological diseases, it can bind specifically to S1P receptors 1, 4, and 5, and may have better efficacy and safety profiles
.
The acquisition will further strengthen Pfizer's diverse and promising portfolio of development-stage therapeutic candidates in gastroenterology, dermatology and cardiology, and accelerate the development of differentiated therapies
for the treatment of multiple immunoinflammatory diseases in candidate candidates such as Etrasimod.
05 Pfizer acquires GBT for $5.
4 billion
4 billion
In October 2022, Pfizer completed its sale on Global Blood for $5.
4 billion
Acquisition
of Therapeutics (GBT).
Founded in 2011 and headquartered in South San Francisco, California, GBT specializes in the development
of treatments for sickle cell disease in SCD.
SCD
It is a lifelong, devastating inherited blood disorder that occurs mainly in
people of African, Middle Eastern and South Asian ancestry.
GBT's Oxbryta (voxelotor) tablet, a drug that directly targets the root cause of SCD, has been approved
in the United States, the European Union, the United Arab Emirates, Oman and the United Kingdom.
Oxbryta's net sales in 2021 were approximately $195 million
.
The acquisition will strengthen Pfizer's presence in rare diseases and accelerate the distribution of GBT's innovative therapies to the
world's most affected regions of SCD.
06 UnitedHealth acquires LHC for $5.
4 billion
4 billion
In October 2022, United Health completed the acquisition
of LHC Group for US$5.
4 billion.
LHC is one of the largest home health care providers in the United States, with 964 offices in 37 states, more than 30,000 employees, and has served 60% of the U.
S.
population aged 65 and over, mainly providing home health services, hospice services, community-based services, facility-based services, and human-computer interaction services
for patients with illness, injury or chronic diseases.
The acquisition will further expand UnitHealth's presence in the home care sector, so that its business covers a diversified service system such as physician groups, clinics, surgical centers and family health, and match LHC's high-quality home and community health services with the value-based care experience and resources of the Optum business segment of UnitedHealth, thereby improving care outcomes and patient experience
.
07 Bristol-Myers Squibb acquires Turning Point Therapeutics for $4.
1 billion
1 billion
In August 2022, Bristol-Myers Squibb BMS acquired all outstanding Turning Point shares
for $76 per share (totaling $4.
1 billion).
Turning
Point
Therapeutics is an innovative company dedicated to developing next-generation anti-cancer therapies that target cancer drivers, with a product line that includes Repotrectinib, TPX-0022, TPX-0046, and the next-generation ALK inhibitor TPS-O131
.
Among them, Repotrectinib is a target
The next generation of potentially best-in-class tyrosine kinase inhibitors driven by ROS1 and NTRK carcinogenicity, thereby strengthening their tumor pipeline for small cell lung cancer and other advanced solid tumors
.
The acquisition will add an important late-stage asset to BMS's leading-edge oncology business and is an important step
in the company's strategy to strengthen external partnerships for business growth.
08 Amgen acquires ChemoCentryx for $3.
7 billion
7 billion
In October 2022, Amgen (AMGN.
US) completed the acquisition of ChemoCentryx for $3.
7 billion
.
ChemoCentryx is a biopharmaceutical company focused on chemokines and chemotaxis systems dedicated to the discovery, development and commercialization of oral medicines for the treatment of rare, inflammatory, autoimmune and cancer
diseases.
The acquisition further strengthens Amgen's global leadership position in inflammation and kidney disease and gives it access to ChemoCentryx's "first-in-class" drug Tavneos for patients with severe autoimmune basal patients, as well as three other early-stage candidates, including ChemoCentryx's "first-in-class" drug for patients with severe autoimmune primaries, as well as three other early-stage candidates
targeting chemokine receptors in other inflammatory diseases and a potentially anti-cancer oral checkpoint inhibitor 。 Among them, the Tavneos drug is indicated for severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, which is used in combination with standard therapy and specifically targets the two main types of ANCA vasculitis, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).
09 GlaxoSmithKline acquires Affinivax for $3.
3 billion
3 billion
In August 2022, GlaxoSmithKline completed the acquisition
of Cambridge, Massachusetts-based manufacturer of pneumococcal vaccines, Affinivax.
Under the terms of the agreement, GlaxoSmithKline acquired
100% of the outstanding shares
of Affinivax.
GlaxoSmithKline paid $2.
1 billion for the acquisition and will make two potential milestone payments of $600 million after Affinivax achieves certain pediatric clinical development milestones
.
Affinivax is a clinical-stage U.
S.
biotechnology company focused on developing next-generation vaccines, with a new MAPS technology platform for vaccines and immunotherapies that will treat pneumococcal diseases including pneumonia, meningitis and sinusitis
.
With this acquisition, GlaxoSmithKline's vaccine pipeline is further strengthened, gaining access to new, potentially breakthrough technologies and further enhancing its competitiveness
in the global market for pneumococcal vaccines.
10 GlaxoSmithKline acquires Sierra Oncology, a U.
S.
biotechnology company, for $1.
9 billion
S.
biotechnology company, for $1.
9 billion
In July 2022, GlaxoSmithKline acquired all of Sierra Oncology's outstanding shares for cash at a price of $55 per share, for a total share capital of approximately $1.
9 billion
.
Sierra
Oncology is a California-based biopharmaceutical company focused on rare tumor-targeted therapies with a pipeline of JAK inhibitors and selective BRD4
BET inhibitors, Chk1 small molecule inhibitors, etc
.
Among them, the main candidate momelotinib is a potent and active selective oral JAK1, JAK2 and ACVR1 inhibitor, and has submitted a new drug application for the treatment of myelofibrosis to the US FDA in June this year, and is expected to be launched
in the United States in 2023.
The acquisition will further strengthen GlaxoSmithKline's expertise in blood therapy, complement its multiple myeloma treatment business, and expand its innovative oncology product line
.
